<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03586414</url>
  </required_header>
  <id_info>
    <org_study_id>17-1782</org_study_id>
    <nct_id>NCT03586414</nct_id>
  </id_info>
  <brief_title>MitoQ Supplementation and Cardiovascular Function in Healthy Men and Women</brief_title>
  <official_title>Mitochondrial Targeted Antioxidant Supplementation and Diastolic Function in Healthy Men and Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Colorado Nutrition Obesity Research Center (NORC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this pilot study, the investigators will determine whether supplementation with a
      mitochondrial-targeted antioxidant (Mitoquinone (MitoQ)) improves mitochondrial function,
      left ventricular diastolic and vascular function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart failure affects over 5 million American adults and the risk of heart failure increases
      with age. Diastolic function typically declines with age. Targeting age-related causal
      factors leading to the decline in diastolic function in both women and men is a major public
      health initiative. In this pilot study, the investigators will determine whether
      supplementation with a mitochondrial-targeted antioxidant (Mitoquinone (MitoQ)) improves
      mitochondrial function, left ventricular diastolic and vascular function in older adults. As
      an exploratory aim, the investigators will determine whether there are differences between
      men and women in response to this supplementation.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    COVID-19
  </why_stopped>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in diastolic function</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Echocardiographic measurements of LV function (and structure) will be assessed; primary outcomes include peak early (E) to late (A) mitral inflow velocity ratio and E to peak early (e') mitral annular velocity ratio.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in arterial stiffness</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Parameters of arterial stiffness will be measured using SphygmoCor XCEL (Atcor) system (pulse-wave velocity [PWV], pulse wave analyses [PWA]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in brachial artery flow-mediated dilation</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Brachial artery diameter and flow velocity will be acquired and analyzed using Vascular Analysis Tools 5.5.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in endothelial function</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Measure parameters using digital peripheral arterial tonometry (Endo-PAT 2000)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in arterial vascular coupling</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Measure ratio between arterial stiffness [Ea] and ventricular stiffness [ELv] estimated from echocardiographic measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in mitochondrial function</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Measure parameters of mitochondrial respiration using high-resolution respirometry performed on permeabilized PBMCs (Oroboros Oxygraph O2k); perform venous endothelial cell mitochondrial protein analyses (Fusion, Fission proteins, SIRT1, mitoSox, MnSOD) and oxidative stress (nitrotyrosine, NADPHoxidase).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diastolic Dysfunction</condition>
  <arm_group>
    <arm_group_label>A: 'MITOQUINOL MESYLATE then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>'MITOQUINOL MESYLATE' administered twice daily for 4 weeks followed by a washout, then placebo capsule administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Placebo then 'MITOQUINOL MESYLATE'</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo capsule administered twice daily for 4 weeks followed by a washout period, then 'MITOQUINOL MESYLATE' administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>MITOQUINOL MESYLATE then placebo</intervention_name>
    <description>MITOQUINOL MESYLATE then placebo: 'MITOQUINOL MESYLATE' administered twice daily for 4 weeks followed by a washout, then placebo capsule administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'.</description>
    <arm_group_label>A: 'MITOQUINOL MESYLATE then placebo</arm_group_label>
    <other_name>MitoQ, Mitoquinol methanesulfonate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo, then MITOQUINOL MESYLATE</intervention_name>
    <description>'Placebo, then MITOQUINOL MESYLATE' : Placebo administered twice daily for 4 weeks followed by a washout, then 'MITOQUINOL MESYLATE' capsule administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'.</description>
    <arm_group_label>B: Placebo then 'MITOQUINOL MESYLATE'</arm_group_label>
    <other_name>MitoQ, Mitoquinol methanesulfonate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 50 - 75 years of age

          2. sedentary-to-recreationally active (&lt;3 days of vigorous exercise);

          3. nonsmokers;

          4. healthy, as determined by medical history, physical examination, standard blood
             chemistries.

        Exclusion Criteria:

          1. history of cancer

          2. history of cardiovascular disease

          3. unwilling or unable to take MitoQ supplement;

          4. taking antioxidant vitamins, corticosteroids, or anti-inflammatory medications (e.g.,
             aspirin);

          5. taking sex hormone therapy

          6. presence of menses within last 1 year;

          7. taking any other medications (e.g., antihypertensives, lipid lowering medications)
             that would interact with MitoQ or impact CV function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shauna Runchey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 21, 2018</study_first_submitted>
  <study_first_submitted_qc>July 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2018</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MitoQ</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ubiquinone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pending</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

